Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Meningitis, Meningococcal Clinical Trial

Official title:

A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04707391
• Other study ID #: 213171
• Secondary ID: 2019-004982-42
• Status: Completed
• Phase: Phase 3
• Start date: January 25, 2021
• Est. completion date: September 29, 2023

Study information

• Verified date: January 2024
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1250
• Est. completion date: September 29, 2023
• Est. primary completion date: May 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years to 25 Years

Eligibility

Inclusion Criteria:

1. Participants and/or participants' parents/LARs, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits).

2. Written or witnessed/thumb printed informed consent obtained from the participant/participant's parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.

3. Written or witnessed/thumb printed informed assent obtained from participants below the legal age of consent prior to performance of any study specific procedure.

4. Previous vaccination with 1 dose of MenACWY vaccine at an age of 10 years or older, with an interval of at least 4 years between the previous MenACWY vaccine and enrollment (informed consent and assent [as applicable]) into this study.

5. A male or female between, and including, 15 and 25 years of age (i.e., 25 years and 364 days) at the time of the first vaccination.

6. Healthy participants as established by medical history, physical examination, and clinical judgment of the investigator before entering into the study.

7. Female participants of non-childbearing potential may be enrolled in the study. Non childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy, or post-menopause.

8. Female participants of childbearing potential may be enrolled in the study, if the participant:

• has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test* on the day of vaccination, and

• has agreed to continue adequate contraception during the entire intervention period and for 30 days after completion of the vaccination series.

Exclusion Criteria:

1. Current or previous, confirmed or suspected disease caused by N. meningitidis.

2. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrollment.

3. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product.

4. Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM 197) and latex medicinal products or medical equipment whose use is foreseen in this study.

5. Progressive, unstable or uncontrolled clinical conditions

6. Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.

7. Abnormal function or modification of the immune system resulting from:

• Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).

• Systemic administration of corticosteroids (oral/intravenous/intramuscular) for more than 14 consecutive days within 90 days prior to study vaccination until the following post vaccination blood sample. This will mean prednisone =20 mg/day (for adult participants and =0.5 mg/kg/day with maximum =20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.

• Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.

• Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab).

8. Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion.

9. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

10. Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study vaccine(s)/product during the period beginning 30 days before the first dose of study vaccine(s)/product (Day -29 to Day 1), or planned use during the study period.

11. Previous vaccination against any group B meningococcal vaccine at any time prior to informed consent and assent as applicable (according to the participant's age).

12. Previous vaccination with 2 or more doses of MenACWY vaccine.

13. Administration/planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before any dose of study vaccine(s)/product until the following post-vaccination blood sample.

14. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to any vaccine/product dose until the following post-vaccination blood sample. For corticosteroids, this will mean prednisone equivalent =20 mg/day for adult participants and =0.5 mg/kg/day with maximum =20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.

15. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product (drug or medical device).

16. Child in care.

17. Pregnant or lactating female.

18. Female planning to become pregnant or planning to discontinue contraceptive precautions.

19. History of/current chronic alcohol and/or drug abuse.

20. Involvement in the study as a study staff member or being immediate dependents, family, or household member of a study staff member.

Related Conditions & MeSH terms

• Meningitis
• Meningitis, Meningococcal

Intervention

Combination Product:
• MenABCWY vaccine
2 doses of MenABCWY vaccine administered intramuscularly on Day 1 and Day 181 to participants in ABCWY group.
• Placebo
1 dose of placebo administered intramuscularly on Day 211 to participants in ABCWY group

Biological:
• MenACWY vaccine
1 dose of MenACWY vaccine administered intramuscularly on Day 1 to participants in ACWY group

Combination Product:
• MenB vaccine
2 doses of MenB vaccine administered intramuscularly on Day 181 and Day 211 to participants in ACWY group. MenB vaccine is a non-investigational medical product (NIMP) in this study and is administered only in compliance with standard of care.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Buenos Aires
Argentina	GSK Investigational Site	Caba	Buenos Aires
Argentina	GSK Investigational Site	Ciudad Autonoma Buenos Aires	Buenos Aires
Argentina	GSK Investigational Site	Ciudad Autonoma de Buenos Aires
Argentina	GSK Investigational Site	Cordoba
Argentina	GSK Investigational Site	Mar del Plata	Buenos Aires
Argentina	GSK Investigational Site	Rio Cuarto
Argentina	GSK Investigational Site	San Miguel de Tucuman	Tucumán
Argentina	GSK Investigational Site	San Miguel de Tucumán	Tucumán
Australia	GSK Investigational Site	Clayton	Victoria
Australia	GSK Investigational Site	Coffs Harbour	New South Wales
Australia	GSK Investigational Site	Darlinghurst	New South Wales
Australia	GSK Investigational Site	Kanwal	New South Wales
Australia	GSK Investigational Site	Maroubra	New South Wales
Australia	GSK Investigational Site	Nedlands	Western Australia
Australia	GSK Investigational Site	Parkville	Victoria
Australia	GSK Investigational Site	Taringa	Queensland
Australia	GSK Investigational Site	Tarragindi	Queensland
Canada	GSK Investigational Site	Guelph	Ontario
Canada	GSK Investigational Site	Sarnia	Ontario
Canada	GSK Investigational Site	Toronto	Ontario
United States	GSK Investigational Site	Albuquerque	New Mexico
United States	GSK Investigational Site	Atlanta	Georgia
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Banning	California
United States	GSK Investigational Site	Beaumont	Texas
United States	GSK Investigational Site	Biloxi	Mississippi
United States	GSK Investigational Site	Boston	Massachusetts
United States	GSK Investigational Site	Carrollton	Texas
United States	GSK Investigational Site	Champaign	Illinois
United States	GSK Investigational Site	Charleston	South Carolina
United States	GSK Investigational Site	Chula Vista	California
United States	GSK Investigational Site	Columbus	Georgia
United States	GSK Investigational Site	Cranberry Township	Pennsylvania
United States	GSK Investigational Site	Dallas	Texas
United States	GSK Investigational Site	Fall River	Massachusetts
United States	GSK Investigational Site	Fayetteville	North Carolina
United States	GSK Investigational Site	Greenville	South Carolina
United States	GSK Investigational Site	Grosse Pointe Woods	Michigan
United States	GSK Investigational Site	Houston	Texas
United States	GSK Investigational Site	Jonesboro	Arkansas
United States	GSK Investigational Site	Katy	Texas
United States	GSK Investigational Site	Kaysville	Utah
United States	GSK Investigational Site	Layton	Utah
United States	GSK Investigational Site	Longview	Texas
United States	GSK Investigational Site	Louisville	Kentucky
United States	GSK Investigational Site	Meridian	Idaho
United States	GSK Investigational Site	Methuen	Massachusetts
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	Monongahela	Pennsylvania
United States	GSK Investigational Site	Pittsburgh	Pennsylvania
United States	GSK Investigational Site	Pittsburgh	Pennsylvania
United States	GSK Investigational Site	Pittsburgh	Pennsylvania
United States	GSK Investigational Site	Plano	Texas
United States	GSK Investigational Site	Port Orange	Florida
United States	GSK Investigational Site	Quincy	Illinois
United States	GSK Investigational Site	Raleigh	North Carolina
United States	GSK Investigational Site	Roslindale	Massachusetts
United States	GSK Investigational Site	Roy	Utah
United States	GSK Investigational Site	Sandy Springs	Georgia
United States	GSK Investigational Site	Seattle	Washington
United States	GSK Investigational Site	Syracuse	Utah
United States	GSK Investigational Site	Syracuse	New York
United States	GSK Investigational Site	The Woodlands	Texas
United States	GSK Investigational Site	Warwick	Rhode Island
United States	GSK Investigational Site	Washington	District of Columbia
United States	GSK Investigational Site	West Covina	California
United States	GSK Investigational Site	Wilmington	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentages of participants with a 4-fold rise in hSBA titers against N. meningitidis serogroups A, C, W, and Y at 1 month after the second MenABCWY vaccine and after the single MenACWY vaccine	Immunogenicity of MenABCWY vaccine after its second dose compared to single dose of MenACWY vaccine, relative to baseline (Day 1) is assessed for each serogroups A, C, W and Y; For each serogroup, the 4-fold rise is defined as: a post-vaccination hSBA titer equal to or higher than (=) 16 for participants with a pre-vaccination hSBA titer <4; a post-vaccination hSBA titer = 4 times the LLOQ for participants with a pre vaccination hSBA titer = limit of detection (LOD) but < LLOQ; and; a post-vaccination hSBA titer = 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer = LLOQ	At 1 month after vaccination schedule (i.e., Day 211 for ABCWY group and Day 31 for ACWY group)
Primary	Percentages of participants with a 4-fold rise in human serum bactericidal assay (hSBA) titers against N. meningitidis serogroups A, C, W, and Y at 1 month after the first MenABCWY vaccine and after the single MenACWY vaccine	Immunogenicity of MenABCWY vaccine after first dose compared to single dose of MenACWY vaccine, relative to baseline (Day 1) is measured. For the serogroups A, C, W, Y, evaluation of the 4-fold rise is defined as: a post-vaccination hSBA titer = 16 for participants with a pre-vaccination hSBA titer <4; . a post-vaccination hSBA titer = 4 times the Lower limit of quantitation (LLOQ) for participants with a prevaccination hSBA titer = limit of detection (LOD) but < LLOQ; and, a post-vaccination hSBA titer = 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer = LLOQ.	At 1 month after the first vaccination (i.e., Day 31)
Primary	Percentages of participants with solicited administration site events	Assessed solicited administrative site events include injection site pain, erythema, swelling, induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters	During the 7 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Primary	Percentages of participants with solicited administration site events	Assessed solicited administrative site events include injection site pain, erythema, swelling, induration. Any erythema, swelling and induration are defined as a symptom with a surface diameter equal to or greater than 25 millimeters.	During the 7 days (including day of vaccination) following vaccination at Day 181 for ABCWY group
Primary	Percentages of participants with solicited systemic events	Assessed solicited systemic events include fever [body temperature = 38.0°C/100.4°F], nausea, fatigue, myalgia, arthralgia, headache.	During the 7 days (including day of vaccination) following vaccination at day 1 for the ABCWY group and ACWY group
Primary	Percentages of participants with solicited systemic events	Assessed solicited systemic events include fever [body temperature = 38.0°C/100.4°F], nausea, fatigue, myalgia, arthralgia, headache	During the 7 days (including day of vaccination) following vaccination at day 181 for the ABCWY group
Primary	Percentages of participants with any unsolicited adverse events (AEs) (including all serious adverse events [SAEs], AEs leading to withdrawal, AEs of special interest [AESIs] and medically attended AEs)	Any AE-untoward medical occurrence in a patient/clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE-AE not solicited using an eDiary and spontaneously communicated by a participant/participant's parent(s)/Legally acceptable representative(s) who has signed informed consent. SAEs-events that result in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is congenital anomaly/birth defect in the offspring of a study participant/results in abnormal pregnancy outcomes. AESIs-predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.	During the 30 days (including day of vaccination) following vaccination at day 1 for ABCWY group and ACWY group
Primary	Percentages of participants with any unsolicited adverse events (AEs) (including all serious adverse events [SAEs], AEs leading to withdrawal, AEs of special interest [AESIs] and medically attended AEs)	Any unsolicited AEs, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs are evaluated	During the 30 days (including day of vaccination) following vaccination at day 181 for ABCWY group
Primary	Percentages of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs	SAEs, AEs leading to withdrawal, AESIs and medically attended AEs are assessed throughout the study period	From Day 1 to Day 361 (throughout the study period)
Secondary	Percentages of participants with hSBA titers = Lower Limit of Quantitation (LLOQ) against serogroups A, C, W, and Y at day 1, 1 month after the first and second MenABCWY vaccine and after the single MenACWY vaccine	Immune response to MenABCWY vaccine after the first and second dose and single dose of MenACWY vaccine is evaluated by measuring the percentage of participants with hSBA titers = LLOQ against each of the serogroups A, C, W and Y	At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group, Day 211 for ABCWY group [second dose])
Secondary	hSBA Geometric Mean Titers (GMTs) against serogroups A, C, W, and Y at day 1, 1 month after the first and second MenABCWY vaccine and after the single MenACWY vaccine	Immune response to MenABCWY after first and second dose and single dose of MenACWY vaccine is evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y in terms of GMTs. For each serogroup, the GMTs with their 95% confidence intervals are calculated.	At Day 1 and 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group, Day 211 for ABCWY group [second dose])
Secondary	Geometric mean ratios (GMRs) against serogroups A, C, W, and Y at 1 month after the first and second MenABCWY vaccine and after the single MenACWY vaccine	Immune response to MenABCWY vaccine after first and second dose and single dose of MenACWY vaccine is evaluated by measuring the human serum bactericidal activity against each of the serogroups A, C, W and Y, compared to baseline (Day 1) and expressed as GMR (GMT after vaccination over GMT at baseline).	At 1 month after the vaccination schedule (i.e., Day 31 for ABCWY group [first dose] and ACWY group, Day 211 for ABCWY group [second dose]) versus Day 1
Secondary	Percentages of participants with hSBA titers = LLOQ for each and all serogroup B indicator strains at day 1 and 1 month after the second dose of MenABCWY vaccine	The immune response to MenABCWY vaccine after second dose is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains- M14459, M13520, 96217and NZ98/254 in terms of percentage of participants with hSBA titers = LLOQ	At Day 1 and Day 211
Secondary	Percentages of participants with 4-fold rise in hSBA titers against each N. meningitidis serogroup B indicator strains at 1 month after the second MenABCWY vaccine	The immune response to MenABCWY after second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains M14459, M13520, 96217and NZ98/254 compared to baseline (day 1) in terms of 4-fold rise in hSBA titers. For each of the serogroup B indicator strains, the 4-fold rise is defined as: a post-vaccination hSBA titer =16 for participants with a pre-vaccination hSBA titer <4; . a post-vaccination hSBA titer = 4 times the LLOQ for participants with a prevaccination hSBA titer = limit of detection (LOD) but < LLOQ; and, a post-vaccination hSBA titer = 4 times the pre-vaccination titer for participants with a pre-vaccination hSBA titer = LLOQ.	At Day 211
Secondary	GMTs against each serogroup B indicator strains at day 1, 1 month after second MenABCWY vaccine	Immune response to MenABCWY vaccine after the second dose is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B indicator strains M14459, M13520, 96217and NZ98/254 in terms of GMTs at baseline (Day 1) and 1 month after second MenABCWY vaccination	At Day 1 and Day 211
Secondary	GMRs against each serogroup B indicator strains at 1 month after second dose of MenABCWY vaccine	Immune response to MenABCWY vaccine after second dose is evaluated by measuring the human serum bactericidal activity against each of the N. meningitidis serogroup B indicator strains- M14459, M13520, 96217and NZ98/254 compared to baseline (Day 1) and expressed as GMR (GMT after vaccination over GMT at baseline).	At Day 211 versus Day 1